SCHEMBL739719

SCHEMBL739719

CC(C)C[C@@H](C=O)NC(=O)OC(C)(C)C

nearest known ligand 0.62

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CTSK P43235 14/20 0.62
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA7 P43166 1/20 0.51
CTSL P07711 2/20 0.49
CTSB P07858 1/20 0.49
CTSS P25774 1/20 0.49
CAPN1 P07384 1/20 0.43
CYP2D6 P10635 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9644705 1.00 CTSK (0.62) CTSKCA1CA2CA7CTSL
SCHEMBL1781832 1.00 CTSK (0.62) CTSKCA1CA2CA7CTSL
SCHEMBL13263255 0.88 CTSK (0.60) CTSKCA1CA2CA7CTSL
SCHEMBL29957942 0.87 CTSK (0.59) CTSKCA1CA2CA7CTSS
SCHEMBL6829984 0.86 CA1 (0.51) CTSKCA1CA2CA7CTSL
SCHEMBL16564868 0.85 CTSK (0.53) CTSKCA1CA2CA7CTSL
SCHEMBL3894401 0.85 CTSK (0.60) CTSKCA1CA2CA7
SCHEMBL22363059 0.85 CTSK (0.60) CTSKCA1CA2CA7
SCHEMBL7433177 0.85 CTSK (0.53) CTSKCA1CA2CA7CTSL
SCHEMBL6786634 0.85 CTSK (0.53) CTSKCA1CA2CA7CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1194449-B1 INHIBITORS OF MEMAPSIN 2 AND USE THEREOF OKLAHOMA MED RES FOUND (US) 2010-09-22 EP claimed
US-7678760-B2 Inhibitors of Memapsin 2 and use thereof THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2010-03-16 US claimed
EP-1819693-B1 ANTITHROMBOTIC DIAMIDES LILLY CO ELI (US) 2009-08-26 EP claimed
US-20090062271-A1 Antithrombotic Diamides ELI LILLY AND COMPANY (US) 2009-03-05 US claimed
US-20080021196-A1 INHIBITORS OF MEMAPSIN 2 AND USE THEREOF THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2008-01-24 US claimed
US-5977371-A Tandem asymmetric transformation process MERCK & CO., INC. (US) 1999-11-02 US claimed
US-4350628-A OXIDATIVE DEHYDROGENATION WITH A BENZOQUINONE RESEARCH CORPORATION (US) 1982-09-21 US claimed
US-12570675-B2 Boronic acid compounds LG CHEM, LTD. (KR) 2026-03-10 US disclosed
EP-4685151-A1 PROTEASOME INHIBITOR Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2026-01-28 EP disclosed
US-20240101579-A1 BORONIC ACID COMPOUNDS LG CHEM, LTD. (KR) 2024-03-28 US disclosed
US-11844776-B2 Composition for treatment and/or prevention of peripheral nerve disorder OSAKA CITY UNIVERSITY (JP) 2023-12-19 US disclosed
US-20230348493-A1 COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) 2023-11-02 US disclosed
CN-116621918-B Spiro compound and preparation method and application thereof 深圳信立泰药业股份有限公司 2023-10-31 CN disclosed
WO-1987005302-A1 NOVEL RENIN-INHIBITING PEPTIDES HAVING A DIHYDROXYETHYLENE ISOSTERE TRANSITION STATE INSERT THE UPJOHN COMPANY (US) 1987-09-11 WO disclosed
EP-0231919-A2 N-Heterocyclic alcohol renin inhibitors E.R. Squibb & Sons, Inc. (US) 1987-08-12 EP disclosed
EP-0218688-A1 DIHALO-STATINE SUBSTITUTED RENIN INHIBITORS. UPJOHN CO (US) 1987-04-22 EP disclosed
EP-0212903-A2 Polypeptide derivatives containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues PFIZER INC. (US) 1987-03-04 EP disclosed
WO-1986006379-A1 DIHALO-STATINE SUBSTITUTED RENIN INHIBITORS THE UPJOHN COMPANY (US) 1986-11-06 WO disclosed
EP-0195212-A2 Novel peptidase inhibitors MERRELL DOW PHARMACEUTICALS INC. (US) 1986-09-24 EP disclosed
US-4596819-A Antidepressive agents WARNER-LAMBERT COMPANY (US) 1986-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348493-A1 COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF GRIN1, GRIN3A, GRIN2C CTSK 4179/4885CA1 972/4885CA2 1310/4885
US-12570675-B2 Boronic acid compounds PSMB6, PSMB3, PSMB2 CTSK 1682/4885CA1 477/4885CA2 309/4885
US-20090062271-A1 Antithrombotic Diamides TFPI, SERPINC1, TFPI2 CTSK 2052/4885CA1 723/4885CA2 960/4885
US-20240101579-A1 BORONIC ACID COMPOUNDS PSMB11, PSMB1, BACH1 CTSK 2553/4885CA1 1530/4885CA2 1672/4885
US-20080021196-A1 INHIBITORS OF MEMAPSIN 2 AND USE THEREOF PSEN2, APP, ANPEP CTSK 2847/4885CA1 2083/4885CA2 2733/4885
US-11844776-B2 Composition for treatment and/or prevention of peripheral nerve disorder PMP22, PRPH, NGF CTSK 4322/4885CA1 3482/4885CA2 2772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.